Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells.
Griessinger
E
E
Frelin
C
C
Cuburu
N
N
Imbert
V
V
Dageville
C
C
Hummelsberger
M
M
Sirvent
N
N
Dreano
M
M
Peyron
J-F
JF
D000818:Animals; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D011743:Pyrimidines / Q000494:pharmacology*; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors*
C519899:AS602868; D016328:NF-kappa B; D011743:Pyrimidines; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3